AU2007272504B2 - Glucocorticoid receptor modulator and methods of use - Google Patents

Glucocorticoid receptor modulator and methods of use Download PDF

Info

Publication number
AU2007272504B2
AU2007272504B2 AU2007272504A AU2007272504A AU2007272504B2 AU 2007272504 B2 AU2007272504 B2 AU 2007272504B2 AU 2007272504 A AU2007272504 A AU 2007272504A AU 2007272504 A AU2007272504 A AU 2007272504A AU 2007272504 B2 AU2007272504 B2 AU 2007272504B2
Authority
AU
Australia
Prior art keywords
compound
chloro
oxa
dibenzo
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007272504A
Other languages
English (en)
Other versions
AU2007272504A1 (en
Inventor
Matthew William Carson
Michael Joseph Coghlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2007272504A1 publication Critical patent/AU2007272504A1/en
Application granted granted Critical
Publication of AU2007272504B2 publication Critical patent/AU2007272504B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007272504A 2006-07-14 2007-07-12 Glucocorticoid receptor modulator and methods of use Ceased AU2007272504B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83116606P 2006-07-14 2006-07-14
US60/831,166 2006-07-14
PCT/US2007/073345 WO2008008882A2 (en) 2006-07-14 2007-07-12 Glucocorticoid receptor modulator and methods of use

Publications (2)

Publication Number Publication Date
AU2007272504A1 AU2007272504A1 (en) 2008-01-17
AU2007272504B2 true AU2007272504B2 (en) 2012-06-28

Family

ID=38924180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007272504A Ceased AU2007272504B2 (en) 2006-07-14 2007-07-12 Glucocorticoid receptor modulator and methods of use

Country Status (14)

Country Link
US (1) US8101760B2 (enExample)
EP (1) EP2043646B1 (enExample)
JP (1) JP5189091B2 (enExample)
KR (1) KR20090020694A (enExample)
CN (1) CN101489556A (enExample)
AU (1) AU2007272504B2 (enExample)
BR (1) BRPI0714811A2 (enExample)
CA (1) CA2655202A1 (enExample)
CL (1) CL2007003501A1 (enExample)
EA (1) EA014695B1 (enExample)
ES (1) ES2384057T3 (enExample)
MX (1) MX2009000583A (enExample)
TW (1) TW200902537A (enExample)
WO (1) WO2008008882A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
ES2370148T3 (es) * 2008-01-11 2011-12-13 Eli Lilly & Company (e)-n-{3-[fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-ciclohepten-5-iliden)-propil]-fenil}-metilsulfonamida como modulador del receptor de glucocorticoides para el tratamiento de artritis reumatoide.
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
JPWO2010001990A1 (ja) * 2008-07-03 2011-12-22 協和発酵キリン株式会社 四環系化合物
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
CN102746219A (zh) * 2012-07-02 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种2-羧基-3-溴吡啶盐酸盐的合成方法
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
JPH01161245A (ja) 1987-12-18 1989-06-23 Canon Inc 電子写真感光体
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5093210A (en) 1989-06-30 1992-03-03 Ricoh Company, Ltd. Electroluminescent device
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
CN101489556A (zh) 2009-07-22
EA014695B1 (ru) 2010-12-30
US20100069425A1 (en) 2010-03-18
TW200902537A (en) 2009-01-16
ES2384057T3 (es) 2012-06-28
CL2007003501A1 (es) 2008-07-04
EP2043646B1 (en) 2012-05-16
WO2008008882A3 (en) 2008-05-02
WO2008008882A2 (en) 2008-01-17
KR20090020694A (ko) 2009-02-26
US8101760B2 (en) 2012-01-24
AU2007272504A1 (en) 2008-01-17
EA200970127A1 (ru) 2009-04-28
CA2655202A1 (en) 2008-01-17
BRPI0714811A2 (pt) 2014-02-18
JP5189091B2 (ja) 2013-04-24
MX2009000583A (es) 2009-01-27
JP2009543804A (ja) 2009-12-10
EP2043646A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
US8101760B2 (en) Glucocorticoid receptor modulator and methods of use
TW539675B (en) Novel 2,3-disubstituted-4(3H)-quinazolinones
JP2019031537A (ja) エストロゲン受容体調節剤としての６，７−ジヒドロ−５ｈ−ベンゾ［７］アヌレン誘導体
AU4501800A (en) Tetracyclic progesterone receptor modulator compounds and methods
US6358947B1 (en) Tetracyclic progesterone receptor modulator compounds and methods
TW201609722A (zh) 新穎三唑并吡啶化合物
CN112771046B (zh) 其他被取代的三唑并喹喔啉衍生物
KR20200084357A (ko) Urat1 억제제의 결정형 및 그의 제조 방법
US7405303B2 (en) Substituted quinoline compounds for use as selective estrogen receptor modulator
CN112218852A (zh) 氧化的双(3-吲哚基)甲烷及其用途
AU2014354085B2 (en) Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
EP2231676B1 (en) (e)-n-{3-[1-(8-fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-cyclohepten-5-ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis
CA2985327A1 (en) Crystal of salt of 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof
CN119768396A (zh) 新颖的取代的苯并噻吩-6-羧酸衍生物、其制备方法及其治疗用途
WO2020192762A1 (zh) 一种a2a受体拮抗剂的盐型、晶型及其制备方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired